A Real-World Evaluation of the Long-Term Safety and Efficacy of Infliximab in the Treatment Moderate-to-Severe Psoriasis

INTRODUCTION: Psoriasis is a chronic immune-mediated inflammatory skin disease that occurs in 2.5–3.5% of the general population. Infliximab (INF), a TNF-α inhibitor biologic agent, is a long-standing efficacious treatment for psoriasis; however, not all patients sustain a long-term response (LTR) b...

Descripción completa

Detalles Bibliográficos
Autores principales: Haque, Emily K., Azhar, Aaminah, Corbett, John, Frieder, Jillian, Wang, Xuan, Menter, Alan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7477063/
https://www.ncbi.nlm.nih.gov/pubmed/32816254
http://dx.doi.org/10.1007/s13555-020-00436-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7477063/
https://www.ncbi.nlm.nih.gov/pubmed/32816254
http://dx.doi.org/10.1007/s13555-020-00436-1

Ejemplares similares